Fujian Cancer Hospital clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 1 with a minor change only.

1. Notable

   PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

   Primary and study completion pushed from Dec 1, 2026 to Sep 1, 2027

   Also in this update: Recruitment opened

   Fujian Cancer Hospital·Phase 2· NCT06788171· Registry history of NCT06788171 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

2. Notable

   MRG003 Induction and Capecitabine Maintenance With PD-1 in…MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

   Recruitment opened

   Fujian Cancer Hospital·Phase 2· NCT07331428· Registry history of NCT07331428 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

3. Notable

   Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT…Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

   Recruitment opened

   Fujian Cancer Hospital·Phase 2· NCT07469306· Registry history of NCT07469306 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.